DRUG
Price
$28.37
Change
+$0.36 (+1.29%)
Updated
Jul 3 closing price
Capitalization
187.21M
ORYZF
Price
$3.22
Change
+$0.19 (+6.27%)
Updated
Jun 9 closing price
Capitalization
245.69M
Interact to see
Advertisement

DRUG vs ORYZF

Header iconDRUG vs ORYZF Comparison
Open Charts DRUG vs ORYZFBanner chart's image
Bright Minds Biosciences
Price$28.37
Change+$0.36 (+1.29%)
Volume$18.96K
Capitalization187.21M
Oryzon Genomics SA
Price$3.22
Change+$0.19 (+6.27%)
Volume$833
Capitalization245.69M
DRUG vs ORYZF Comparison Chart in %
Loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DRUG vs. ORYZF commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and ORYZF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (DRUG: $28.37 vs. ORYZF: $3.22)
Brand notoriety: DRUG and ORYZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 46% vs. ORYZF: 33%
Market capitalization -- DRUG: $187.21M vs. ORYZF: $245.69M
DRUG [@Biotechnology] is valued at $187.21M. ORYZF’s [@Biotechnology] market capitalization is $245.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileORYZF’s FA Score has 0 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • ORYZF’s FA Score: 0 green, 5 red.
According to our system of comparison, both DRUG and ORYZF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 5 TA indicator(s) are bullish while ORYZF’s TA Score has 3 bullish TA indicator(s).

  • DRUG’s TA Score: 5 bullish, 4 bearish.
  • ORYZF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, DRUG is a better buy in the short-term than ORYZF.

Price Growth

DRUG (@Biotechnology) experienced а +14.49% price change this week, while ORYZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

DRUG is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORYZF($246M) has a higher market cap than DRUG($187M). ORYZF YTD gains are higher at: 98.969 vs. DRUG (-21.238). ORYZF has higher annual earnings (EBITDA): 834K vs. DRUG (-2.67M). DRUG has more cash in the bank: 57.9M vs. ORYZF (8.44M). DRUG has less debt than ORYZF: DRUG (183K) vs ORYZF (13.4M). DRUG (0) and ORYZF (0) have equivalent revenues.
DRUGORYZFDRUG / ORYZF
Capitalization187M246M76%
EBITDA-2.67M834K-320%
Gain YTD-21.23898.969-21%
P/E RatioN/AN/A-
Revenue00-
Total Cash57.9M8.44M686%
Total Debt183K13.4M1%
TECHNICAL ANALYSIS
Technical Analysis
DRUGORYZF
RSI
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
40%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
40%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
29%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
20%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
18%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
8%
View a ticker or compare two or three
Interact to see
Advertisement
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFPDX12.740.17
+1.35%
Allspring Premier Large Co Gr Adm
JSMGX27.900.26
+0.94%
Janus Henderson Triton I
NMIMX28.140.24
+0.86%
Columbia Large Cap Enhanced Core Inst
ENHCX10.530.02
+0.19%
Cullen Enhanced Equity Income C
CCISX11.43-0.01
-0.09%
Calamos International Small Cap Gr C

ORYZF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORYZF has been loosely correlated with CLDI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORYZF jumps, then CLDI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
N/A
CLDI - ORYZF
37%
Loosely correlated
+5.09%
PPBT - ORYZF
28%
Poorly correlated
+3.33%
DRUG - ORYZF
25%
Poorly correlated
+1.29%
GNNSF - ORYZF
24%
Poorly correlated
N/A
IPSC - ORYZF
20%
Poorly correlated
+0.02%
More